Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects of and how well alisertib works in treating
young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.